熄风定颤胶囊治疗帕金森病模型大鼠的实验研究
|
摘要
帕金森病(PD)是目前较为公认的一种难治的、缓慢进展的原因不明的脑病，尚没有十分满意的治疗方法。本文用熄风定颤胶囊灌胃给药的方法对PD模型大鼠进行了治疗，观察熄风定颤胶囊对PD模型大鼠行为学的影响；并测定熄风定颤胶囊对PD模型大鼠纹状体丙二醛(MDA)、超氧化物歧化酶(SOD)、谷光甘肽(GSH)、谷胱甘肽过氧化物酶(GSH-PX)含量的影响；观测熄风定颤胶囊对PD模型大鼠黑质酪氨酸羟化酶(TH)的影响。
本实验将6-羟基多巴胺(6-OHDA)注入大鼠纹状体制备PD模型大鼠，设计并成功地对PD模型大鼠进行了熄风定颤胶囊灌胃给药治疗，发现给药后PD模型大鼠的行为学有了显著改善(p＜0.01)。同时，纹状体丙二醛(MDA)含量下降，而谷胱甘肽(GSH)、谷胱甘肽过氧化物酶(GSH-PX)含量升高，说明中药熄风定颤胶囊可以增强PD模型大鼠的抗氧化应激能力，从而减少氧化应激反应所致的DA能神经元损伤。组织形态学检测发现，酪氨酸羟化酶(TH)阳性细胞增加，证实了给予PD模型大鼠熄风定颤胶囊，增加了TH的阳性表达，从而减轻PD型大鼠的旋转行为。本实验不但证明了中药熄风定颤胶囊治疗PD的方法是可行的，而且是行之有效的；同时揭示了熄风定颤胶囊治疗PD模型大鼠的作用机制，从而为中药治疗PD奠定了理论与实验基础，为PD的治疗提供了一种新的思路和方法。
It is accepted at present that Parkinson's disease(PD) is an Idiopathic encephalopathy to be slowly progressive and intractable, and has no satisfying methods to treat yet.
This paper describes and discusses a method to cure the PD-model white rat by giving the TCM of Xi-feng-ding-chan capsule and its influence to rat behavior, relevant bio-chemical criterion and histomorphology.
In this experiment, author prepares a PD-model white rat by injecting the 6-OHDA into the rat's caudate putamen(CPu), and succeeds in designing and giving the TCM of Xi-feng-ding-chan capsule to the rats. As a result, rat not only survival but also remarkable improvement(p＜0.01)in behavior after being given the TCM of Xi-feng-ding-chan capsule. At same time, MDA content decrease, the content of GSH and GSH-PX increase, so the TCM of Xi-feng-ding-chan capsule can improve anti-oxygenstress ability of PD-model white rat, and abate lethal damage to dopaminergic neurons bringing out by anti-oxygen stress.
Histomorphology detection suggests that TH-positive cells increase after TCM treatment, and that demonstrate that TCM of Xi-feng-ding-chan capsule can increase the expression of TH-positive cells, and thereby inhibit the rat rotation behaviour.
This experiment proves the TCM of Xi-feng-ding-chan capsule not only feasible but also valid; at one time, it make clear the function mechanism of this kind of TCM, and establishes a theoretical and experimental basis for curing PD by the TCM of Xi-feng-ding-chan capsule, and provides a new idea and method.
本实验将6-羟基多巴胺(6-OHDA)注入大鼠纹状体制备PD模型大鼠，设计并成功地对PD模型大鼠进行了熄风定颤胶囊灌胃给药治疗，发现给药后PD模型大鼠的行为学有了显著改善(p＜0.01)。同时，纹状体丙二醛(MDA)含量下降，而谷胱甘肽(GSH)、谷胱甘肽过氧化物酶(GSH-PX)含量升高，说明中药熄风定颤胶囊可以增强PD模型大鼠的抗氧化应激能力，从而减少氧化应激反应所致的DA能神经元损伤。组织形态学检测发现，酪氨酸羟化酶(TH)阳性细胞增加，证实了给予PD模型大鼠熄风定颤胶囊，增加了TH的阳性表达，从而减轻PD型大鼠的旋转行为。本实验不但证明了中药熄风定颤胶囊治疗PD的方法是可行的，而且是行之有效的；同时揭示了熄风定颤胶囊治疗PD模型大鼠的作用机制，从而为中药治疗PD奠定了理论与实验基础，为PD的治疗提供了一种新的思路和方法。
It is accepted at present that Parkinson's disease(PD) is an Idiopathic encephalopathy to be slowly progressive and intractable, and has no satisfying methods to treat yet.
This paper describes and discusses a method to cure the PD-model white rat by giving the TCM of Xi-feng-ding-chan capsule and its influence to rat behavior, relevant bio-chemical criterion and histomorphology.
In this experiment, author prepares a PD-model white rat by injecting the 6-OHDA into the rat's caudate putamen(CPu), and succeeds in designing and giving the TCM of Xi-feng-ding-chan capsule to the rats. As a result, rat not only survival but also remarkable improvement(p＜0.01)in behavior after being given the TCM of Xi-feng-ding-chan capsule. At same time, MDA content decrease, the content of GSH and GSH-PX increase, so the TCM of Xi-feng-ding-chan capsule can improve anti-oxygenstress ability of PD-model white rat, and abate lethal damage to dopaminergic neurons bringing out by anti-oxygen stress.
Histomorphology detection suggests that TH-positive cells increase after TCM treatment, and that demonstrate that TCM of Xi-feng-ding-chan capsule can increase the expression of TH-positive cells, and thereby inhibit the rat rotation behaviour.
This experiment proves the TCM of Xi-feng-ding-chan capsule not only feasible but also valid; at one time, it make clear the function mechanism of this kind of TCM, and establishes a theoretical and experimental basis for curing PD by the TCM of Xi-feng-ding-chan capsule, and provides a new idea and method.
引文
1．王维治．神经病学．人民卫生出版社，2002：206
2．陈生弟．我国帕金森病的研究进展．中国神经免疫学和神经病学杂志，2001．4(2)：67～693．孙斌．临床内科杂志，1999，16(3)58～59
4．李世绰，程学铭，等．神经系统疾病流行病学．人民卫生出版社，2002，141～142
5．刘悼霖，张成，等．第13届国际帕金森病会议纪要．中华神经科杂志，2000，4(2)：123～125
6．陈彪，等．帕金森病病因研究．中山医科大学学报，1991，12：143～146
7．杨金升，等．帕金森病病因危险因素的病例一对照研究．中华流行病学杂志，1994，15：6～9
8. Cao T, et al. Fsctors for Parkinson's disease. Neurology, 1993,43:1693～1697
9. Michele GD, etal. Etiology of Parkinson's disease:the role of environment and Heredity. Adv In Neurol, 1996,69:19～24
10. Semchukk, etal. Parkinson's disease andwxposure to rural environmental factors:a population based case-control study. Gan J Neurol Sci, 1991,18:279～286
11. Godwin-Austin RB, et al. Smoking and Parkinson's disease. J Neurol Neurosurg Psychiat, 1982,45:577～581
12. Grandinetti A, et al. Prospective Study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol, l994,139:1129～1138
13. Morens DM, et al. Cigarette smoking andproteetion for Parkinson's disease:false Associationor etiologic clue? Neurology, 1995,45:1041～1051
14．常喝咖啡可防帕金森病．摘自三九健康网
15. Li SC, et al.A prevalence survey of Parkinson's disease andother movement disorders in the People's Republic of China. Arch Neuro1985,42:655
16. Logroscino G, et al. Dietary lipids and antioxidants in Parkinson's disease:a populationbased, case-control studym Ann Neurol, 1996,39:89～94
17. Naoi M, Marayama W, Mech Ageing Dev, 1999,111(2～3): 175～188
18. Olanow CW An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol, 1992,32;S2～S9
19. Semchuk KM, et al. Parkinson's disease:a test of the mufti-factorial etiologic hypothesis. Neurology, 1993' 43:1173～180
20．史玉泉．神经病学新理论与新技术．上海科技教育出版社，1998 344～345
21. Riederer P, et al. J Neurochem, 1989,52:515
22. Ambani LM, et aLArchNeurol, 1985,32:114
23. Dexter DT, et al. Lipid peroxidation, as cause of nigral cell death in Parkinson's disease. Lancet, 1986,2639
24．Adams JD，氧自由基和帕金森病．国外医学老年医学分册，1992，5(3)105～108
25．朱酒欣．帕金森病的病因．临床神经科学，1994，1：51～56
26．李振光．从自由基学说探讨帕金森病．国外医学老年分册，1994，15(1)：1～3
27．高占国，刘传绩．MPTP的神经毒性与帕金森病动物模型．国外医学神经病学神经外科学分册，1995，22(5)：228～230
28. Sethi D, et al. Neuroepidemiology of Parkinson's disease:analysis of motality data for the U.S.A and Geogia. Int J Neurosci, 1989,46:87～92
29. Langton JW, Ballard P, Tetrad JW, et al. Chronic Parkinsonism in human due to a product of mepe-ridineanalog synthesis.Science, 1983,219:979～980
30. Roman GC, Zhang ZX. The neuroepidemiology of Parkinson's disease. In, Ellenberg JH, et al(eds).Etiology of Parkinson's disease. 1994
31. zhang ZX,Roman GC. Worldwide occurrence of Parkinson's disease:an up-date review. Neuroepi-demiology, 1993,12:195
32．荣娟，陈生弟．帕金森病与遗传因素．中华老年医学杂志1999，6(3)：180～182
33. Poly meropolons MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21～q23
34．范国华．a-synuclein与帕金森病．中国神经免疫学和神经病学杂志2001，4(2)：105～107
35. Agundez JA, Jimenez-Jimenez FJ, Zuengo A, et al. Stow allotypic variants of the NAT 2 gene and susceplibility to erty-oaset Pkinson's disease. Neurology, 1998,51:1587～1592
36. Hattori N, et al, Bioxhen Biophys Res Commun, 1998, 249: 754
37．柏华．parkin基因与帕金森病．菌外医学神经病学．神经外科分册，1999，26(3)：：149～152
38. Mizuno Y, Shimoda MaxsubayaslS, MatsumineH, etal. Genetica and Environmental factors in the pathogenesis of Parkinson's disease. Asv Neurol, 1999, 80: 171～179
39．王建，刘焯霖，等．细胞色素P4502E1基因5’侧翼区多态性与帕金森病遗传易患性的关系．中华神经科杂志，1999，32：167
40．王建，刘焯霖，等．细胞色素P450IA1基因多态性与帕金森病的关系．中华神经科杂志1999，32：337
41. Bandmann O, Vaughan J, Holmans P, et al Association of slow familial Parkinson's disease. Lancet, 1997, 50:1136～1139
42. Schapira AHV, et al. Mitochon drial Functionin Parkinson's disease Ann Neurol, 1992,32:S116～S124
43．高枫，陈清棠，等．帕金森病患者线粒体功能缺陷的研究．中华神经科杂志1999，8(4)：199～201
44. ViereggeP. Genitic factors in the etiology of idiopathic Parkinson's disease. J Neurol Transm(P-DSect),1994,8:1～37
45. Whetsell WO. Current concept ofexcitaxicity. Neurolody, 1996,55(1):1～13
46. Simpson JR, Isacson O. Mitochondrial impairment reduces the threshold for in vivo NMDA-Mediated neuronal death in the striatum. Exp Neurol,1993;121:57～60
47. Kikuchi S, Kim SV Glutamate neurotoxicity on mesen-dephalic dopamin ergic neuronsin culture. J Neurosci Res, 1993;36:558～569
48. Connor JJO, WuJ,RowanMJ et al. Neuroscience, 1995;69(2):363
49. ZivI, Melamed E, Nard;et al. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons: a possible novel pathogenetic in Parkinsons diseasese. Neurosci Zett, 1994,170:136
50. TompkinsMM, Basgall EJ, Zamrini E, et al,Apoptotic-lik changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons, Am J Pathol 1997,150:119
51．孙涛．帕金森病与细胞凋亡．实用老年医学，2001，15(1)：46～48
52．徐仁侧，等．帕金森病的病理生理机制研究进展．国外医学．生理．病理科学与临床分册，1999，19(6)：461 463
53．刘小琴．某些神经疾病的生物化学．摘自37℃医学网．文献资料．相关医学理论．
54．李建生．常见老年神经精神疾病现代治疗．中国中医药出版社，1998 294～313
55．周文泉，李祥国。实用中医老年病学．人民卫生出版，2000，777～778
56．社刘振国，陈生弟，等．帕金森病功能显像实验研究．中国神经精神疾病杂志，2000．26(4)：56～59
57．刘振国，陈生弟等．Tc-TRODAT-1放射自显影对PD模型多巴胺转运蛋白的观察．中华老年医学杂志，2000．19(3)：3235
58．胡平．陈玲等．Tc-TRODAT-1人脑多巴胺转运体显像初步研究．中国神经精神疾病杂志，2000，26(4)：5255
59. Marderyk, Tang MX, Cote L, et al. The frequency and associated
60. Mardery K,Tang MX,Cote L,et al. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol, 1995,52:695～701.
61．马建军，孙翠萍，李德霞，等．帕金森病患者的智能及事件相关电位研究．中华老年医学杂志，1996，15：97～100．
62. Tsai CH, Lu CS, Hua MS,et al. Cognitive dysfunction in early onset parkisonism. Acta Neurol Scand, 1994,89:9～14.
63. Piccitrilli M, DAlessandro P, Finali G, et al. Neuropsychological follow-up Of parkinsonian patients with and without cognitive impairment. Dementia, 1994,5:17～22.
64. Cummings JL. Depression and Parkinson's disease: a review. Arn J Psychiatry, 1992,149:443～454.
65. Menza MA, Mark MH. Parkinson's disease and depression: the relationship to disability and personality. J Neuropsychiatry Clin Neurosci, 1994,6:165～69.
66. Glosser G, Clark C, Freundlich B, et al.A controlled investigation of can ent and Premorbid personality: characteristics of Parkinson's, disease patients. Mov Disord, 1995,10:201～206.
67．陈蓓，刘剑立，王耀山，等．震颇麻痹与智能障碍．中国神经精神疾病杂志，1990，16：17-1～173．
68. Kitagawa M, Fukushima J, Tashiro K, et al. Relationship between antisaccades, and the clinical symptoms in Parkinson's disease. Neurology, 1994,44:2285～2289.
69．胡昌恒，袁光固，罗祖明，等．帕金森病的神经心理学研究．中华神经精神杂志，1985，18：219～221．
70. Sandyk R, Improvement in short-term visual memory by weak electrom agnetic fields in Pakinson's disease. Int J Neurosci, 1995,81:67～82.
71．陈先文；陈生弟．帕金森病的药物治疗进展．摘自nhhn-gd-cn/yikj/sj．
72．杨立恩．抗帕金森病药物治疗的现状与新近展．摘自秦脉医学网．专业资讯．秦脉医学杂志
73. PoeweWH. Clinical aspects of motor fluctuations in Parkinson's disease. Neurology. 1994,44(supp6):S6
74. Koller WC, Pahwa R. Treating motor fluctuations, with controlled-release levodopa preparations. Neurology, 1994,44(suppl 6):S23
75. Mizun Y,kondo T, Mori H. Yarous aspects of motol fluctuations andtheir managementin Parkinson's disease. Neurology, 1994,44(suppl):S29
76．孙斌．帕金森病的药物治疗现状．中国综合临床，1999，15(4)：295～297
77．王新德．略论帕金森病的药物治疗问题．中华神经科杂志，1997，30(4)：197
78. Poewe WH, Caraceni T. Dopamine agonists in the treatment of Parkinson' s disease. Neurology, 1995, 45(suppl 3):S5
79. Wolters EC, Tiddingh G, Bergmans PLM, et al. Dopamine agonists in Parkinson's disease. Neurology, 1995, 45(suppl 3);S28
80. Jenner P The ratonale for the use of dopamihe agonists in Parkinson's disease. Neurology, 1995, 45(suppl 3);S28
81. Mizuno Y, Kondo T, Nerabayashi H. Pergolide in the treatment Of Parkinson's disease. Neurology, 1995, 45(suppl 3):13
82．孙斌，罗毅．硫丙麦角林治疗帕金森病23例临床观察．卒中与神经疾病，1999，6(2)：107～109
83. Pezzoli G, Martignoni E, Pacchetti C, et aLA crossover, controlledstude comparing pergolide with bromocriptine asan adjinct to levosopafoi the treatment of Parkinson's disease. Neurology, 1995, 45(suppl 3); S22
84．孙斌，罗毅．丙炔苯丙胺治疗帕金森病30例临床观察．卒中与神经疾病，1997，4(2)：60～62
85. Paola iZD, Uitti. Treatment implications in the early detection of Parkinson's disease. Medical Progress SEA, 1997,24(1):8
86．刘焯霖，陈生弟．第12届国际帕金森病会议纪要．中华神经科杂志，1997．，30(4)：254
87．刘道宽．帕金森病新疗法的研究动态．中华神经科杂志，1997，30(4)：242
88．徐仁佃．帕金森病的外科治疗现状．国外医学．老年医学分册，1999，(4)：155
89．陈彪，李勇杰．苍白球损毁术治疗帕金森病的现状．中华神经内科杂志，1999，(4)：197
90．李勇杰．帕金森病的手术治疗．现代康复，2000，4(3)特集：28～31
91．罗尉峰．深部脑刺激治疗帕金森病．国外医学．老年医学分册，2001，(3)：112～114
92. Cross C et al.J Neurosurg, 1997,87:491
93. Benasid AL et al.J Neurostrg, 1994,62;76
94. Limousin P et al. Lancet, 1995;345:91
95. Gross'RE, Lombardi WJ, Hutchison WD et al: Variadility in lesion location aftermicroelectrode-guided pallidotomy for Parkinson's disease: anatomical, physiological, and technical factors that determine lesion distribution. J Neurosurg. 1999,90,468-47
96. Kondziolka D et al.J Neurosurg, 1999,90:197
97. Laitinen L V, Bergenheim A T, Hariz MI, et al. Lekse110s posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg, 1992, 76(3):53
98. Laitinen L V,Bergenheim A T, Hariz Ml, et al. Ventroposteral pallidotomy can abolish all Parkinsonian symptoms. Stereotact Funct Neurosurg, 1992, 58(6):14
99．伦学庆，章翔，等．高频电刺傲丘脑底核治疗帕金森病的实验研究．功能性和立体定向神经外科杂志，1997(1)：1
100．高学廉，高国栋。帕金森病微电极导向手术后并发症的探讨．中国神经精神杂志，2001，(4)：267～268’
101. Wolff JA,Fisher LJ,Xu L,et ai. Grafting fibrobiasts genetically modified to produce Lee dope in a rat model of Parkinson disease[J]. Proceedings of the National Academy of Sciences of the United States of America,1989,86:901I
102. Lin LFH, Doherty DH, LiIe J D, et al.GDNF-A glial cell Line derived neurotrophic factor for midbraih dopaminergic neurons.Science,1993 260:1130
103．罗涌，梁希彬，王晓民．帕金森病基因治疗的研究进展．现代康复，2000．4(3)特集：38～40
104．段德义，徐群渊。帕金森病基因治疗实验研究中治疗基因的选择．解剖学报。2000，31(0)52～55
105．徐强，徐如祥．帕金森病基，因治疗实验研究进展．国外医学．神经病学神经外科学分1999，26(6)：317～320
106．任继学．震颇麻痹辨证论治[[J]．江苏中医杂志，19824：11
107．李文伟．帕金森病中西医结合研究的现状及进展．上海中医药杂志，1998，(6)：45～47
108．樊鉴，周仲瑛．治疗震颇麻痹的经验[J]．中医杂志，1996，37(11)：663
109．邹忆怀．王永炎教授治疗颇振病(帕金森氏病)经验探讨．北京中医药大学学报，1996，16(4)：15～16
110．王坤山，王慧艳一试谈震颇麻痹辨治体会[[J]．甘肃中医，1993，6(2)：8
111．潘橙攘．震颇麻痹病的证治操讨闭．浙江中医杂志，1990，11：483
112．王瑞海．震颇证临床治疗概述．山东中医杂志，1990，(1)：57～59
113．隆呈祥，邹忆怀，韩晓军，等．中药颇振平治疗老年颇证临床和实验研究．北京中医药大学学报，199922(6)：28～32
114．曾宪贵．育阴活络汤治疗四肢颇震44例．辽宁中医杂志，1990(6)：16
115．许世平．逍遥散加减治疗老年震颇30例观察．河北中医，1994．(1)：29～30
116．徐尚华．复方养血熄风汤治疗震颇麻痹病．浙江中医杂志，1994，(12)：534～535
117．王素娥，廖新华．辨证论治结合五虫散治疗老年震颤麻痹．中级医刊，1992．(11)：59～60
118．潘文奎．中医治疗帕金森氏病的信息分析．中国中医药信息杂志，1996，(1)：19～21
119．刘秦．试论中医对震颇麻痹的认识．广西中医药，1989，(27)：25～27
120．亲德远，案树永．老年颇证治疗四法．山东中医杂志，1993，(4)：12～13
121．宰春和，窦林午，张志雄，等．震颇麻痹的中医辨证和中西医结合治疗．上海中医药杂志，1981(5)：16～17
122．王永炎，蒋达树，侯力娜，等．中医药治疗震颇麻痹综合征35例疗效观察．中医杂志1986，(8)：22～24
123. Davis GC, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues,Psychiatry Res 1979;1:249.
124. Sayre LM.Biochemical mechanism of the dopaminergic neurotoxinl-me thyl-4-pheny ridine(MPTP)[J], Toxicol Lett, 1989,48(2): 121～149
125．伦学庆，张延庆，章翔．帕金森病实验动物模型研究进展．立体定向和功能性神经外科杂志，12(2)：39～41
126. Ditazio MC. Hollingsworth Z, Young AB. et al. Glutamate receptors in the substantia nigro of parkinson's disease brain. Neurology,1992, 42:402～406.
127．高占国，刘传绩．MPTP的神经毒性与帕金森病动物模型，国外医学神经病学神经外科学分册，1995，22(S)：228～230
128. Giovanni A et al.J Pharmacol Exp Ther,1991,257:691
129．梁希彬，周宁，谢俊霞，王小民．大鼠帕金森病模型的建立及其评价．中国神经科学杂志，2000，16(3)：65～67
130．罗海燕，彭国光一经多巴胺帕金森病动物模型的研究．国外医学神经病学神经外科学分册，1999，26(6)：283～285 ’
131. Sauer H, Oertel WH. Progressive degeneration of nigrostriatal dopamine neurons Following intrastriatal terminal lesionns with 6-hydroxydopamine:A combined retrograde tracing and immunocytoChem. -ical study in the rat. Neuroscience, 1994, 54:401.
132.Maneuf YP,Duty S,Hille CJ,et al.Modulation of GAGA transmission by diazoxide and cromakalim in the globus pallidus:implications for the treatment of Parkinson's disease[J]. Exp Neurol, 1996, 139:12～16
133. Ben-Shachar Youdim MBH. Intranigral iron injection induces behavioral and biochemical"Parkinsonism" in rats.J Neurochem, 1991,57:2133～2135
134. Ogata A, Tashiro K, Nukuzuma S, et al. A rat model of Parkinson's disease induced by Japanese encephalitis virus[J]. J Neurovirol, 1997,3:141～147
135．李文伟，蔡定芳，陈小红，等．帕金森病大鼠神经行为和中脑酪氨酸轻化酶mRNA表达的改变．中华老年医学杂志，2000 19(6)：439～441
136. Glinka YY,Youdim MBH. Luhibition of mitochondrial complex Ⅰ and Ⅳ by 6-hydroxydopamine[J]. Eur J Pharmacol[Environm Toxicol Phamacol Sect], 1995, 292:329～332
137．艾民康．神经介质及有关酶类的组织化学．人民卫生出版社，1987．66～68
138. John D E, Robert H R.Dopamine synthesis,uptake, metabolism,and recepto rs:rele vance to gene therapy of Parkinson's disease[J]. Exp Neurol,1997,144(1):4-9.[ZK]
139. Kastner A,Hirsch EC,Agid Y,et al.Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease.Brain Res, 1993; 606: 341～345
2．陈生弟．我国帕金森病的研究进展．中国神经免疫学和神经病学杂志，2001．4(2)：67～693．孙斌．临床内科杂志，1999，16(3)58～59
4．李世绰，程学铭，等．神经系统疾病流行病学．人民卫生出版社，2002，141～142
5．刘悼霖，张成，等．第13届国际帕金森病会议纪要．中华神经科杂志，2000，4(2)：123～125
6．陈彪，等．帕金森病病因研究．中山医科大学学报，1991，12：143～146
7．杨金升，等．帕金森病病因危险因素的病例一对照研究．中华流行病学杂志，1994，15：6～9
8. Cao T, et al. Fsctors for Parkinson's disease. Neurology, 1993,43:1693～1697
9. Michele GD, etal. Etiology of Parkinson's disease:the role of environment and Heredity. Adv In Neurol, 1996,69:19～24
10. Semchukk, etal. Parkinson's disease andwxposure to rural environmental factors:a population based case-control study. Gan J Neurol Sci, 1991,18:279～286
11. Godwin-Austin RB, et al. Smoking and Parkinson's disease. J Neurol Neurosurg Psychiat, 1982,45:577～581
12. Grandinetti A, et al. Prospective Study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol, l994,139:1129～1138
13. Morens DM, et al. Cigarette smoking andproteetion for Parkinson's disease:false Associationor etiologic clue? Neurology, 1995,45:1041～1051
14．常喝咖啡可防帕金森病．摘自三九健康网
15. Li SC, et al.A prevalence survey of Parkinson's disease andother movement disorders in the People's Republic of China. Arch Neuro1985,42:655
16. Logroscino G, et al. Dietary lipids and antioxidants in Parkinson's disease:a populationbased, case-control studym Ann Neurol, 1996,39:89～94
17. Naoi M, Marayama W, Mech Ageing Dev, 1999,111(2～3): 175～188
18. Olanow CW An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol, 1992,32;S2～S9
19. Semchuk KM, et al. Parkinson's disease:a test of the mufti-factorial etiologic hypothesis. Neurology, 1993' 43:1173～180
20．史玉泉．神经病学新理论与新技术．上海科技教育出版社，1998 344～345
21. Riederer P, et al. J Neurochem, 1989,52:515
22. Ambani LM, et aLArchNeurol, 1985,32:114
23. Dexter DT, et al. Lipid peroxidation, as cause of nigral cell death in Parkinson's disease. Lancet, 1986,2639
24．Adams JD，氧自由基和帕金森病．国外医学老年医学分册，1992，5(3)105～108
25．朱酒欣．帕金森病的病因．临床神经科学，1994，1：51～56
26．李振光．从自由基学说探讨帕金森病．国外医学老年分册，1994，15(1)：1～3
27．高占国，刘传绩．MPTP的神经毒性与帕金森病动物模型．国外医学神经病学神经外科学分册，1995，22(5)：228～230
28. Sethi D, et al. Neuroepidemiology of Parkinson's disease:analysis of motality data for the U.S.A and Geogia. Int J Neurosci, 1989,46:87～92
29. Langton JW, Ballard P, Tetrad JW, et al. Chronic Parkinsonism in human due to a product of mepe-ridineanalog synthesis.Science, 1983,219:979～980
30. Roman GC, Zhang ZX. The neuroepidemiology of Parkinson's disease. In, Ellenberg JH, et al(eds).Etiology of Parkinson's disease. 1994
31. zhang ZX,Roman GC. Worldwide occurrence of Parkinson's disease:an up-date review. Neuroepi-demiology, 1993,12:195
32．荣娟，陈生弟．帕金森病与遗传因素．中华老年医学杂志1999，6(3)：180～182
33. Poly meropolons MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21～q23
34．范国华．a-synuclein与帕金森病．中国神经免疫学和神经病学杂志2001，4(2)：105～107
35. Agundez JA, Jimenez-Jimenez FJ, Zuengo A, et al. Stow allotypic variants of the NAT 2 gene and susceplibility to erty-oaset Pkinson's disease. Neurology, 1998,51:1587～1592
36. Hattori N, et al, Bioxhen Biophys Res Commun, 1998, 249: 754
37．柏华．parkin基因与帕金森病．菌外医学神经病学．神经外科分册，1999，26(3)：：149～152
38. Mizuno Y, Shimoda MaxsubayaslS, MatsumineH, etal. Genetica and Environmental factors in the pathogenesis of Parkinson's disease. Asv Neurol, 1999, 80: 171～179
39．王建，刘焯霖，等．细胞色素P4502E1基因5’侧翼区多态性与帕金森病遗传易患性的关系．中华神经科杂志，1999，32：167
40．王建，刘焯霖，等．细胞色素P450IA1基因多态性与帕金森病的关系．中华神经科杂志1999，32：337
41. Bandmann O, Vaughan J, Holmans P, et al Association of slow familial Parkinson's disease. Lancet, 1997, 50:1136～1139
42. Schapira AHV, et al. Mitochon drial Functionin Parkinson's disease Ann Neurol, 1992,32:S116～S124
43．高枫，陈清棠，等．帕金森病患者线粒体功能缺陷的研究．中华神经科杂志1999，8(4)：199～201
44. ViereggeP. Genitic factors in the etiology of idiopathic Parkinson's disease. J Neurol Transm(P-DSect),1994,8:1～37
45. Whetsell WO. Current concept ofexcitaxicity. Neurolody, 1996,55(1):1～13
46. Simpson JR, Isacson O. Mitochondrial impairment reduces the threshold for in vivo NMDA-Mediated neuronal death in the striatum. Exp Neurol,1993;121:57～60
47. Kikuchi S, Kim SV Glutamate neurotoxicity on mesen-dephalic dopamin ergic neuronsin culture. J Neurosci Res, 1993;36:558～569
48. Connor JJO, WuJ,RowanMJ et al. Neuroscience, 1995;69(2):363
49. ZivI, Melamed E, Nard;et al. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons: a possible novel pathogenetic in Parkinsons diseasese. Neurosci Zett, 1994,170:136
50. TompkinsMM, Basgall EJ, Zamrini E, et al,Apoptotic-lik changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons, Am J Pathol 1997,150:119
51．孙涛．帕金森病与细胞凋亡．实用老年医学，2001，15(1)：46～48
52．徐仁侧，等．帕金森病的病理生理机制研究进展．国外医学．生理．病理科学与临床分册，1999，19(6)：461 463
53．刘小琴．某些神经疾病的生物化学．摘自37℃医学网．文献资料．相关医学理论．
54．李建生．常见老年神经精神疾病现代治疗．中国中医药出版社，1998 294～313
55．周文泉，李祥国。实用中医老年病学．人民卫生出版，2000，777～778
56．社刘振国，陈生弟，等．帕金森病功能显像实验研究．中国神经精神疾病杂志，2000．26(4)：56～59
57．刘振国，陈生弟等．Tc-TRODAT-1放射自显影对PD模型多巴胺转运蛋白的观察．中华老年医学杂志，2000．19(3)：3235
58．胡平．陈玲等．Tc-TRODAT-1人脑多巴胺转运体显像初步研究．中国神经精神疾病杂志，2000，26(4)：5255
59. Marderyk, Tang MX, Cote L, et al. The frequency and associated
60. Mardery K,Tang MX,Cote L,et al. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol, 1995,52:695～701.
61．马建军，孙翠萍，李德霞，等．帕金森病患者的智能及事件相关电位研究．中华老年医学杂志，1996，15：97～100．
62. Tsai CH, Lu CS, Hua MS,et al. Cognitive dysfunction in early onset parkisonism. Acta Neurol Scand, 1994,89:9～14.
63. Piccitrilli M, DAlessandro P, Finali G, et al. Neuropsychological follow-up Of parkinsonian patients with and without cognitive impairment. Dementia, 1994,5:17～22.
64. Cummings JL. Depression and Parkinson's disease: a review. Arn J Psychiatry, 1992,149:443～454.
65. Menza MA, Mark MH. Parkinson's disease and depression: the relationship to disability and personality. J Neuropsychiatry Clin Neurosci, 1994,6:165～69.
66. Glosser G, Clark C, Freundlich B, et al.A controlled investigation of can ent and Premorbid personality: characteristics of Parkinson's, disease patients. Mov Disord, 1995,10:201～206.
67．陈蓓，刘剑立，王耀山，等．震颇麻痹与智能障碍．中国神经精神疾病杂志，1990，16：17-1～173．
68. Kitagawa M, Fukushima J, Tashiro K, et al. Relationship between antisaccades, and the clinical symptoms in Parkinson's disease. Neurology, 1994,44:2285～2289.
69．胡昌恒，袁光固，罗祖明，等．帕金森病的神经心理学研究．中华神经精神杂志，1985，18：219～221．
70. Sandyk R, Improvement in short-term visual memory by weak electrom agnetic fields in Pakinson's disease. Int J Neurosci, 1995,81:67～82.
71．陈先文；陈生弟．帕金森病的药物治疗进展．摘自nhhn-gd-cn/yikj/sj．
72．杨立恩．抗帕金森病药物治疗的现状与新近展．摘自秦脉医学网．专业资讯．秦脉医学杂志
73. PoeweWH. Clinical aspects of motor fluctuations in Parkinson's disease. Neurology. 1994,44(supp6):S6
74. Koller WC, Pahwa R. Treating motor fluctuations, with controlled-release levodopa preparations. Neurology, 1994,44(suppl 6):S23
75. Mizun Y,kondo T, Mori H. Yarous aspects of motol fluctuations andtheir managementin Parkinson's disease. Neurology, 1994,44(suppl):S29
76．孙斌．帕金森病的药物治疗现状．中国综合临床，1999，15(4)：295～297
77．王新德．略论帕金森病的药物治疗问题．中华神经科杂志，1997，30(4)：197
78. Poewe WH, Caraceni T. Dopamine agonists in the treatment of Parkinson' s disease. Neurology, 1995, 45(suppl 3):S5
79. Wolters EC, Tiddingh G, Bergmans PLM, et al. Dopamine agonists in Parkinson's disease. Neurology, 1995, 45(suppl 3);S28
80. Jenner P The ratonale for the use of dopamihe agonists in Parkinson's disease. Neurology, 1995, 45(suppl 3);S28
81. Mizuno Y, Kondo T, Nerabayashi H. Pergolide in the treatment Of Parkinson's disease. Neurology, 1995, 45(suppl 3):13
82．孙斌，罗毅．硫丙麦角林治疗帕金森病23例临床观察．卒中与神经疾病，1999，6(2)：107～109
83. Pezzoli G, Martignoni E, Pacchetti C, et aLA crossover, controlledstude comparing pergolide with bromocriptine asan adjinct to levosopafoi the treatment of Parkinson's disease. Neurology, 1995, 45(suppl 3); S22
84．孙斌，罗毅．丙炔苯丙胺治疗帕金森病30例临床观察．卒中与神经疾病，1997，4(2)：60～62
85. Paola iZD, Uitti. Treatment implications in the early detection of Parkinson's disease. Medical Progress SEA, 1997,24(1):8
86．刘焯霖，陈生弟．第12届国际帕金森病会议纪要．中华神经科杂志，1997．，30(4)：254
87．刘道宽．帕金森病新疗法的研究动态．中华神经科杂志，1997，30(4)：242
88．徐仁佃．帕金森病的外科治疗现状．国外医学．老年医学分册，1999，(4)：155
89．陈彪，李勇杰．苍白球损毁术治疗帕金森病的现状．中华神经内科杂志，1999，(4)：197
90．李勇杰．帕金森病的手术治疗．现代康复，2000，4(3)特集：28～31
91．罗尉峰．深部脑刺激治疗帕金森病．国外医学．老年医学分册，2001，(3)：112～114
92. Cross C et al.J Neurosurg, 1997,87:491
93. Benasid AL et al.J Neurostrg, 1994,62;76
94. Limousin P et al. Lancet, 1995;345:91
95. Gross'RE, Lombardi WJ, Hutchison WD et al: Variadility in lesion location aftermicroelectrode-guided pallidotomy for Parkinson's disease: anatomical, physiological, and technical factors that determine lesion distribution. J Neurosurg. 1999,90,468-47
96. Kondziolka D et al.J Neurosurg, 1999,90:197
97. Laitinen L V, Bergenheim A T, Hariz MI, et al. Lekse110s posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg, 1992, 76(3):53
98. Laitinen L V,Bergenheim A T, Hariz Ml, et al. Ventroposteral pallidotomy can abolish all Parkinsonian symptoms. Stereotact Funct Neurosurg, 1992, 58(6):14
99．伦学庆，章翔，等．高频电刺傲丘脑底核治疗帕金森病的实验研究．功能性和立体定向神经外科杂志，1997(1)：1
100．高学廉，高国栋。帕金森病微电极导向手术后并发症的探讨．中国神经精神杂志，2001，(4)：267～268’
101. Wolff JA,Fisher LJ,Xu L,et ai. Grafting fibrobiasts genetically modified to produce Lee dope in a rat model of Parkinson disease[J]. Proceedings of the National Academy of Sciences of the United States of America,1989,86:901I
102. Lin LFH, Doherty DH, LiIe J D, et al.GDNF-A glial cell Line derived neurotrophic factor for midbraih dopaminergic neurons.Science,1993 260:1130
103．罗涌，梁希彬，王晓民．帕金森病基因治疗的研究进展．现代康复，2000．4(3)特集：38～40
104．段德义，徐群渊。帕金森病基因治疗实验研究中治疗基因的选择．解剖学报。2000，31(0)52～55
105．徐强，徐如祥．帕金森病基，因治疗实验研究进展．国外医学．神经病学神经外科学分1999，26(6)：317～320
106．任继学．震颇麻痹辨证论治[[J]．江苏中医杂志，19824：11
107．李文伟．帕金森病中西医结合研究的现状及进展．上海中医药杂志，1998，(6)：45～47
108．樊鉴，周仲瑛．治疗震颇麻痹的经验[J]．中医杂志，1996，37(11)：663
109．邹忆怀．王永炎教授治疗颇振病(帕金森氏病)经验探讨．北京中医药大学学报，1996，16(4)：15～16
110．王坤山，王慧艳一试谈震颇麻痹辨治体会[[J]．甘肃中医，1993，6(2)：8
111．潘橙攘．震颇麻痹病的证治操讨闭．浙江中医杂志，1990，11：483
112．王瑞海．震颇证临床治疗概述．山东中医杂志，1990，(1)：57～59
113．隆呈祥，邹忆怀，韩晓军，等．中药颇振平治疗老年颇证临床和实验研究．北京中医药大学学报，199922(6)：28～32
114．曾宪贵．育阴活络汤治疗四肢颇震44例．辽宁中医杂志，1990(6)：16
115．许世平．逍遥散加减治疗老年震颇30例观察．河北中医，1994．(1)：29～30
116．徐尚华．复方养血熄风汤治疗震颇麻痹病．浙江中医杂志，1994，(12)：534～535
117．王素娥，廖新华．辨证论治结合五虫散治疗老年震颤麻痹．中级医刊，1992．(11)：59～60
118．潘文奎．中医治疗帕金森氏病的信息分析．中国中医药信息杂志，1996，(1)：19～21
119．刘秦．试论中医对震颇麻痹的认识．广西中医药，1989，(27)：25～27
120．亲德远，案树永．老年颇证治疗四法．山东中医杂志，1993，(4)：12～13
121．宰春和，窦林午，张志雄，等．震颇麻痹的中医辨证和中西医结合治疗．上海中医药杂志，1981(5)：16～17
122．王永炎，蒋达树，侯力娜，等．中医药治疗震颇麻痹综合征35例疗效观察．中医杂志1986，(8)：22～24
123. Davis GC, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues,Psychiatry Res 1979;1:249.
124. Sayre LM.Biochemical mechanism of the dopaminergic neurotoxinl-me thyl-4-pheny ridine(MPTP)[J], Toxicol Lett, 1989,48(2): 121～149
125．伦学庆，张延庆，章翔．帕金森病实验动物模型研究进展．立体定向和功能性神经外科杂志，12(2)：39～41
126. Ditazio MC. Hollingsworth Z, Young AB. et al. Glutamate receptors in the substantia nigro of parkinson's disease brain. Neurology,1992, 42:402～406.
127．高占国，刘传绩．MPTP的神经毒性与帕金森病动物模型，国外医学神经病学神经外科学分册，1995，22(S)：228～230
128. Giovanni A et al.J Pharmacol Exp Ther,1991,257:691
129．梁希彬，周宁，谢俊霞，王小民．大鼠帕金森病模型的建立及其评价．中国神经科学杂志，2000，16(3)：65～67
130．罗海燕，彭国光一经多巴胺帕金森病动物模型的研究．国外医学神经病学神经外科学分册，1999，26(6)：283～285 ’
131. Sauer H, Oertel WH. Progressive degeneration of nigrostriatal dopamine neurons Following intrastriatal terminal lesionns with 6-hydroxydopamine:A combined retrograde tracing and immunocytoChem. -ical study in the rat. Neuroscience, 1994, 54:401.
132.Maneuf YP,Duty S,Hille CJ,et al.Modulation of GAGA transmission by diazoxide and cromakalim in the globus pallidus:implications for the treatment of Parkinson's disease[J]. Exp Neurol, 1996, 139:12～16
133. Ben-Shachar Youdim MBH. Intranigral iron injection induces behavioral and biochemical"Parkinsonism" in rats.J Neurochem, 1991,57:2133～2135
134. Ogata A, Tashiro K, Nukuzuma S, et al. A rat model of Parkinson's disease induced by Japanese encephalitis virus[J]. J Neurovirol, 1997,3:141～147
135．李文伟，蔡定芳，陈小红，等．帕金森病大鼠神经行为和中脑酪氨酸轻化酶mRNA表达的改变．中华老年医学杂志，2000 19(6)：439～441
136. Glinka YY,Youdim MBH. Luhibition of mitochondrial complex Ⅰ and Ⅳ by 6-hydroxydopamine[J]. Eur J Pharmacol[Environm Toxicol Phamacol Sect], 1995, 292:329～332
137．艾民康．神经介质及有关酶类的组织化学．人民卫生出版社，1987．66～68
138. John D E, Robert H R.Dopamine synthesis,uptake, metabolism,and recepto rs:rele vance to gene therapy of Parkinson's disease[J]. Exp Neurol,1997,144(1):4-9.[ZK]
139. Kastner A,Hirsch EC,Agid Y,et al.Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease.Brain Res, 1993; 606: 341～345